Invasive Fungal Disease
1
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
GS
BP
Basilea PharmaceuticaSwitzerland - Allschwil
1 programFungiScope - A Global Emerging Fungal Infection RegistryN/A
PfizerNEW YORK, NY
1 programFungiScope - A Global Emerging Fungal Infection RegistryN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Gilead SciencesLiposomal amphotericin B
PfizerFungiScope - A Global Emerging Fungal Infection Registry
Clinical Trials (2)
Total enrollment: 1,355 patients across 2 trials
Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia
Start: Apr 2011Est. completion: Jan 2014355 patients
Phase 3Completed
FungiScope - A Global Emerging Fungal Infection Registry
Start: Mar 2003Est. completion: Dec 20261,000 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,355 patients
3 companies competing in this space